ClinicalTrials.gg
RecruitingNCT05972317Updated Oct 15, 2026

IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial

An interventional study of Standard Low FODMAP dietary regimen and personalized low FODMAP dietary regimen in Irritable Bowel Syndrome, sponsored by Weizmann Institute of Science. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Weizmann Institute of Science · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 15, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Irritable Bowel Syndrome with a site in Israel — 2 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · Israel.

Planned enrollment
9th of 10
30 · median 110
Started
2026
with 1 other
No phase
5 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Weizmann Institute of Science

Among the 11 studies in Irritable Bowel Syndrome with a site in Israel, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 10th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

2 of the 11 studies in Irritable Bowel Syndrome with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Irritable Bowel Syndrome with a site in Israel, or all of them as a file.
02

Study summary

Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. This placebo-controlled interventional study examines person-specific small molecules and bacteria driving IBS and their downstream effects on the human gut epithelium.

Read the detailed description

This interventional study will include volunteers who are suspected of suffering from IBS. They will be asked to fill several questionnaires: Rome IV Diagnostic Questionnaire for Irritable Bowel Syndrome (R4DQ), irritable bowel syndrome - Symptom Severity Scale (IBS-SSS), irritable bowel syndrome - Quality of Life survey (IBS-QOL) and a food frequency questionnaire (FFQ). Blood tests including Celiac serology will be taken, as well as stool for home Calprotectin test. participants will be asked to collect stool samples at home.

If the participant has a recent, relevant medical documents, they will be asked to provide them to the study team for further evaluation of IBS diagnosis.

Gastroenterologist will receive anonymized patients data - for validation and final diagnosis of IBS.

At the end of the screening period, participants without a gastroenterologist's approval - will end their participation in the study, whereas participants who will be deemed fit, will continue to the next phase and will be allocated randomly to one of the two arms to start the nutritional intervention:

  1. Standard low FODMAP dietary regimen randomized re-introduction phase
  2. Standard low FODMAP dietary regimen with personalized re-introduction phase

Participants will be asked to record daily activities, food intake, Bristol stool scale, and symptoms on a smartphone application during the elimination and reintroduction phases. Participants will be given kits to collect stool samples at home during all study phases.

The dietitian follow-up meetings will be held on a weekly basis during the elimination and re-introduction phases via phone/video call or frontal meeting. Dietitian counseling will include the Monash University's low FODMAP diet app guidance.

03

Conditions studied

  • Irritable Bowel Syndrome
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female
  • Age - 18-70

Exclusion criteria

Exclusion Criteria:

  • Consumption of antibiotics 2 months prior to enrolment.
  • Consumption of probiotic supplements 2 weeks prior to enrolment.
  • Type 1 or type 2 diabetes diagnosis.
  • Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study.
  • Chronic disease - to the discretion of the study medical team.
  • Cancer and recent anticancer treatment.
  • .
  • Psychiatric disorders - to the discretion of the medical team
  • History of gastrointestinal surgeries - to the discretion of the medical team
  • Inflammatory bowel diseases or gastrointestinal disorders - to the discretion of the medical team
  • Unstable doses of medications in the past 2 months
  • Alcohol or substance abuse.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    IBS - standard low FODMAP

    individuals that are diagnosed with IBS according to Rome IV criteria Standard low FODMAP dietary regimen randomized re-introduction phase

    Other: Standard Low FODMAP dietary regimen

  • Experimental
    IBS - personalised low FODMAP

    individuals that are diagnosed with IBS according to Rome IV criteria FODMAP dietary regimen with personalized re-introduction phase

    Other: personalized low FODMAP dietary regimen

Interventions

  • OtherStandard Low FODMAP dietary regimen

    Standard low FODMAP dietary regimen randomized re-introduction phase

  • Otherpersonalized low FODMAP dietary regimen

    Low FODMAP dietary regimen with personalized re-introduction phase

06

What researchers measure

Primary outcomes

  1. Stool microbiome composition

    metagenomic sequencing of stool samples

    Time frame: 4 months

Secondary outcomes

  1. IBS-SSS - irritable bowel syndrome severity score system questionnaire

    Severity of symptoms as they are scored in the Rome IV IBS-SSS 75 to \<175 to indicate mild IBS, 175 to \<300 as moderate, and \>300 as severe

    Time frame: 4 months

Other outcomes

  1. IBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaire

    Quality of life scores from the Rome IV IBS-QOL 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2023
First posted
Aug 2, 2023
StartActual
May 11, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Nov 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
100→30
Oct 15, 2026
Eligibility
4 exclusion criteria edited, 4 added, 2 removed
What changed in the criteria
Exclusion criteria
  • EditedConsumption of antibiotics 2 months prior to the first day of the experimentenrolment.
  • EditedConsumption of probiotic supplements 1 month2 weeks prior to the first day of the experimentenrolment.
  • EditedChronic disease - to the discretion of the study doctormedical team.
  • AddedImmunosuppression.
  • EditedPsychiatric disorders - to the discretion of the study doctor.medical team
  • RemovedIBD (inflammatory bowel diseases).
  • AddedHistory of gastrointestinal surgeries - to the discretion of the medical team
  • AddedInflammatory bowel diseases or gastrointestinal disorders - to the discretion of the medical team
  • AddedUnstable doses of medications in the past 2 months
  • RemovedBMI > 35.
Oct 15, 2026
Interventions
Added Standard Low FODMAP dietary regimen·personalized low FODMAP dietary regimen; removed Low FODMAP dietary regimen. Arm changed IBS -low FODMAP→IBS - standard low FODMAP. Arms added: IBS - personalised low FODMAP; arms removed: Non-IBS
Oct 15, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedStool microbiome compositionTime frame: 4 months
  • RemovedIBS-SSS - irritable bowel syndrome severity score system questionnaireTime frame: 1 week
  • RemovedIBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaireTime frame: 1 week
Oct 15, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • ChangedBefore Stool microbiome differences between the study arms - using fecal samples of participantsNow IBS-SSS - irritable bowel syndrome severity score system questionnaireTime frame: 3 months → 4 months
  • Addedother outcomeIBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaireTime frame: 4 months
Oct 15, 2026
Title
The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients→IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Enrollment 100→30
    Eligibility 4 exclusion criteria edited, 4 added, 2 removed
    What changed in the criteria
    Exclusion criteria
    • EditedConsumption of antibiotics 2 months prior to the first day of the experimentenrolment.
    • EditedConsumption of probiotic supplements 1 month2 weeks prior to the first day of the experimentenrolment.
    • EditedChronic disease - to the discretion of the study doctormedical team.
    • AddedImmunosuppression.
    • EditedPsychiatric disorders - to the discretion of the study doctor.medical team
    • RemovedIBD (inflammatory bowel diseases).
    • AddedHistory of gastrointestinal surgeries - to the discretion of the medical team
    • AddedInflammatory bowel diseases or gastrointestinal disorders - to the discretion of the medical team
    • AddedUnstable doses of medications in the past 2 months
    • RemovedBMI > 35.
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedStool microbiome compositionTime frame: 4 months
    • RemovedIBS-SSS - irritable bowel syndrome severity score system questionnaireTime frame: 1 week
    • RemovedIBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaireTime frame: 1 week
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • ChangedBefore Stool microbiome differences between the study arms - using fecal samples of participantsNow IBS-SSS - irritable bowel syndrome severity score system questionnaireTime frame: 3 months → 4 months
    • Addedother outcomeIBS-QOL questionnaire - irritable bowel syndrome quality of life questionnaireTime frame: 4 months
    Interventions Added Standard Low FODMAP dietary regimen·personalized low FODMAP dietary regimen; removed Low FODMAP dietary regimen. Arm changed IBS -low FODMAP→IBS - standard low FODMAP. Arms added: IBS - personalised low FODMAP; arms removed: Non-IBS
    Title The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients→IBS Personalized Diet vs. Low FODMAP Diet Randomized Control Trial
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05972317
Lead sponsor
Weizmann Institute of Science
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
May 11, 2026
Primary completion
Jan 2028 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Yotam Cohen
Contact
Yotam.cohen@weizmann.ac.il
+97289529173
Shimrit Eliyahu Miller
Contact
shimrit.miller@weizmann.ac.il
Eran Elinav, Prof
principal investigator · Weizmann Institute of Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion